Influenza A virus neuraminidase subtype N9 (NA N9)

Influenza A virus neuraminidase N9 is a viral surface enzyme responsible for cleaving terminal sialic acid residues from glycoproteins and glycolipids on host cells and viral particles, facilitating the release and spread of progeny viruses[1][5]. It is one of nine canonical influenza A neuraminidase subtypes, encoded on the sixth segment of the viral genome, and is predominantly found in avian influenza A viruses such as H7N9. The enzyme's active site is highly conserved and crucial for viral lifecycle, making NA N9 a validated therapeutic target for influenza antivirals[2][4]. Inhibitors and neutralizing antibodies can effectively prevent virus propagation, but evolutionary mutations may lead to resistance, presenting challenges for drug development and therapeutic durability[2][4]. NA N9 also serves as an important antigen for vaccine and monoclonal antibody research, with distinct antigenic sites characterized by structural studies[4].

Other names

NA N9Influenza neuraminidase N9Sialidase N9

Competitive inhibition of neuraminidase active site by sialic acid analogues, preventing the cleavage of sialic acid and thereby blocking viral release and spread. Neutralization with monoclonal antibodies that block the enzyme active site or allosteric epitopes.